Crescent Biopharma (CBIO) Cash & Equivalents (2013 - 2026)

Crescent Biopharma (CBIO) has reported Cash & Equivalents for 14 consecutive years, with $171.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 12.42% year-over-year to $171.6 million; the TTM figure through Jun 2026 stood at $171.6 million (up 12.42% YoY), while the FY2025 annual figure was $213.2 million, up 513.22% from the prior year.
• Cash & Equivalents slipped to $171.6 million in Q2 2026 per CBIO's latest filing, from $189.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $213.2 million in Q4 2025 and bottomed at $14.4 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $79.8 million across 5 years, with a median of $54.8 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 70.85% — and 2025, when it jumped 825.69%.
• Crescent Biopharma's Cash & Equivalents stood at $47.9 million in 2022, then decreased by 12.7% to $41.8 million in 2023, then retreated by 16.81% to $34.8 million in 2024, then surged by 513.22% to $213.2 million in 2025, then dropped by 19.51% to $171.6 million in 2026.
• Business Quant data shows CBIO's Cash & Equivalents at $171.6 million in Q2 2026, $189.2 million in Q1 2026, and $213.2 million in Q4 2025.